Replies to post #54854 on Ariad Pharmaceuticals Inc fka ARIA

[Hotrodder1]

Great post!

[zuize]

There is a ongoing campaign for ousting Harvey Berger; they said that if this occurred ARIA share price would be doubled instantly without the details on how it would assuredly happen.

It has been mentioned on this message board with the incident in 2008 in which almost of half of members on the board had to resign abruptly (basically surrendered to the almighty Harvey Berger.) Assuming that they were correct on Denner’s purpose for joining Ariad to battle HB to take full control of the company, then how many board members Denner would need on his side in order to win the battle, and how he would be able to achieve that given the poison pill?

Harvey Berger is a rich man with plenty of money in the bank (from selling ARIA in $20s and the annual exercising his stock option grants) . At the age of 65 with only a couple more years to run the company, money is no longer important. What most important to him is the legacy he’s going to leave at Ariad when going into retirement. He wants the day leaving Ariad as a great man who built Ariad into a prominent pharmar co with strong product in the market. Being ousted at this state is a total disgrace to him no matter how much he would gain from this. So he will fight to last breath and things will become real messy, Ariad stock price will tank further.

I don’t think the shorts are too ignorant of the 2008 incident, and they know for sure that Denner would be going to lose the battle against HB, and he would have to resign board and sell all his shares just like what happened to Ariad in 2008; the stock was traded at $4.25 on 1/1/2008 and closed at $0.85 by the end of the year on 12/31/2008.

[jq1234]

Did you actually read what you posted? Quite a rationalization on the one year anniversary! I guess nothing learned, there is nothing wrong with Iclusig, nothing wrong with management's decisions regarding dosage in the past, it's FDA's fault, it's shorts' fault. LOL! Iclusig's safety issue was out there all of last year unless you buried your head in the sand, it didn't come out of blue all of sudden like AFFY's Omontys. I am sure at least in the back of your mind for the past year, you wished you had listened to "shorts" just for this one time.

If there is anything wrong with FDA's decision making, it shouldn't have granted Iclusig broad 2nd line label in the first place, later it simply took away what it shouldn't have granted based on clinical trial data submitted.


>> Therefore, it’s just doesn’t make sense at all for looking into a common dosage applied for all especially when dealing with those highly potent cancer drugs.


If that's the case, it is a COMPANY's responsibility to figure out whether one dose fits all or certain dose for some people while another dose for other people. You should blame them for not thinking of this solution in the first place!